Sign In
Buy CADL
$8.80
+0.380 (+4.51%)
At Close: Jun 03, 2026
Candel Therapeutics reports breakthrough data for late-stage lung cancer – ICYMI
09:19am, Saturday, 29'th Mar 2025
Candel Therapeutics Inc (NASDAQ:CADL) earlier this week shared updated clinical data from a Phase 2a study evaluating its immunotherapy candidate CAN-2409 in patients with advanced non-small cell lun
Candel Therapeutics reports positive survival data for CAN-2409 in advanced lung cancer trial
04:21pm, Wednesday, 26'th Mar 2025
Candel Therapeutics Inc (NASDAQ:CADL) said on Wednesday that its experimental immunotherapy, CAN-2409, demonstrated prolonged median overall survival in a Phase 2a clinical trial for patients with adv
NEEDHAM, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Bears are Losing Control Over Candel Therapeutics (CADL), Here's Why It's a 'Buy' Now
10:55am, Tuesday, 25'th Mar 2025
Candel Therapeutics (CADL) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions coul
Candel Therapeutics partners with IDEA Pharma on commercialization of lead asset CAN-2409
10:04am, Thursday, 20'th Mar 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced that it has partnered with IDEA Pharma to advance the commercialization of its lead immunotherapy candidate CAN-2409. The collaboration follows positive
Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409
08:00am, Thursday, 20'th Mar 2025
NEEDHAM, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics appoints cancer immunology expert to research advisory board
09:32am, Tuesday, 18'th Mar 2025
Candel Therapeutics Inc (NASDAQ:CADL) said on Tuesday it has appointed Dr Elizabeth Jaffee to its research advisory board. Jaffee, an internationally recognized expert in cancer immunology and pancrea
Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.
08:00am, Tuesday, 18'th Mar 2025
NEEDHAM, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics eyes CAN-2409 BLA filing, advances cancer pipeline
04:41pm, Thursday, 13'th Mar 2025
Candel Therapeutics Inc (NASDAQ:CADL) said on Thursday it is preparing to submit a Biologics License Application (BLA) for its lead candidate, CAN-2409, in prostate cancer, as the company pushes forwa
Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights
04:15pm, Thursday, 13'th Mar 2025
NEEDHAM, Mass., March 13, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologi
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial results - ICYMI
03:49pm, Friday, 28'th Feb 2025
Candel Therapeutics Inc (NASDAQ:CADL) CEO Dr Paul Peter Tak talked with Proactive about the encouraging results from the phase 2 trial of its investigational medicine CAN-2409 for borderline resectabl
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data
04:52pm, Tuesday, 25'th Feb 2025
Candel Therapeutics' recent phase 2 results in pancreatic cancer showed promising median survival but led to a 20% stock drop due to market skepticism. Despite the drop, I maintain a "Buy" sentiment,
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy
09:08am, Tuesday, 25'th Feb 2025
Candel Therapeutics Inc (NASDAQ:CADL) announced positive final overall survival data from its Phase 2 clinical trial of CAN-2409, an investigational immunotherapy for pancreatic ductal adenocarcinoma
NEEDHAM, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing multimodal biologic
Candel Therapeutics: Entering Its Pivotal Year
10:45am, Thursday, 20'th Feb 2025
Candel Therapeutics' lead candidate CAN-2409 shows promising results in several indications. CAN-2409's Phase 2a pancreatic cancer study could be released this quarter, and its prostate cancer drug co
